I am responsible for the management and oversight of pharmacy utilization within the University of Michigan’s prescription drug plan. In this role I manage the plan’s formulary, perform comprehensive drug utilization reviews, and develop and implement clinical programs.
Pharmacy School Attended: University of Michigan (2012)
- PGY1 Pharmacy Residency: Diplomat Specialty Pharmacy (2013)
- Masters in Science, Pharmacoeconomics: University of Florida (2015)
- Bachelors of Science: University of Georgia (2007)
Areas of Interest
Formulary management, pharmacoeconomics, and outcomes research.
Honors & Awards
AMCP Experiential Education Preceptor Award (2020)
AMCP Gold Metal Abstract (2019)
Published Articles or Reviews
Gowda C, Lott S, Grigorian M, Carbonari D, Saine M, Trooskin S, Roy J, Kostman J, Urick P, Lo Re V. Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study. Open Forum Infect Dis. 2018 June; 6(5):ofy076.
Andres J, Lott S, Qureshi K. Eight-Week Outcomes of Ledipasvir/Sofosbuvir in Noncirrhotic Treatment-Naive Patients with Hepatitis C: Analysis of Pharmacy-Based Data. J Manag Care Spec Pharm. 2018 Jan;24(1):23-28.
Kowdley KV, Sundaram V, Jeon CY, Qureshi K, Latt NL, Sahota A, Lott S, Curry MP, Tsai N, Chaiyakunapruk N, Lee Y, Petersen J, Buggisch P. Eight weeks of Ledipasvir/Sofosbuvir is effective for selected patients with genotype 1 Hepatitis C virus infection. Hepatology. 2017 Apr; 65(4):1094-1103.
Lott S, Burghart K, Burghart P, Bly M, Ellingrod V. The influence of metabolic syndrome, physical activity, and genotype on catechol-o-methyl transferase promoter-region methylation in schizophrenia. Pharmacogenomics J. 2013 Jun; 13(3):264-71.
Warrenfeltz SW, Lott S, Palmer TM, Gray JC, Puett D. Luteinizing hormone-induced up-regulation of ErbB-2 is insufficient stimulant of growth and invasion in ovarian cancer cells. Mol Cancer Res. 2008 Nov; (6)11: 1775-85.